NewAmsterdam Pharma Company N.V./$NAMS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
Ticker
$NAMS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
77
ISIN
NL00150012L7
Website
NAMS Metrics
BasicAdvanced
$2.1B
-
-$1.85
-0.02
-
Price and volume
Market cap
$2.1B
Beta
-0.02
52-week high
$26.95
52-week low
$14.06
Average daily volume
856K
Financial strength
Current ratio
19.977
Quick ratio
19.761
Long term debt to equity
0.018
Total debt to equity
0.05
Profitability
EBITDA (TTM)
-189.582
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-397.45%
Operating margin (TTM)
-402.49%
Effective tax rate (TTM)
0.00%
Revenue per employee (TTM)
$610,000
Management effectiveness
Return on assets (TTM)
-18.15%
Return on equity (TTM)
-31.51%
Valuation
Price to revenue (TTM)
39.645
Price to book
2.66
Price to tangible book (TTM)
2.66
Price to free cash flow (TTM)
-13.28
Free cash flow yield (TTM)
-7.53%
Free cash flow per share (TTM)
-138.93%
Growth
Revenue change (TTM)
586.97%
Earnings per share change (TTM)
-32.18%
3-year revenue growth (CAGR)
-2.29%
3-year earnings per share growth (CAGR)
110.07%
Bulls say / Bears say
NewAmsterdam Pharma's obicetrapib has shown positive topline data in pivotal Phase 3 BROOKLYN and TANDEM clinical trials, indicating potential for regulatory approval and market success. (marketscreener.com)
The company has a strong cash position, with $808.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025, providing financial stability for ongoing and future projects. (biospace.com)
Analysts have a 'Strong Buy' consensus on NAMS stock, with a price target of $43.17, suggesting significant upside potential from the current price. (stockanalysis.com)
NewAmsterdam Pharma reported a net loss of $39.5 million for the quarter ended March 31, 2025, indicating ongoing financial challenges. (biospace.com)
The company's revenue is heavily reliant on milestone payments, with $3.0 million recognized in Q1 2025, which may not be sustainable long-term. (biospace.com)
Despite positive trial results, obicetrapib has yet to receive regulatory approval, and any delays or issues in the approval process could negatively impact the stock. (marketscreener.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
NAMS News
AllArticlesVideos
NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial
GlobeNewsWire·3 weeks ago
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
GlobeNewsWire·3 weeks ago
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NewAmsterdam Pharma Company N.V. stock?
NewAmsterdam Pharma Company N.V. (NAMS) has a market cap of $2.1B as of June 27, 2025.
What is the P/E ratio for NewAmsterdam Pharma Company N.V. stock?
The price to earnings (P/E) ratio for NewAmsterdam Pharma Company N.V. (NAMS) stock is 0 as of June 27, 2025.
Does NewAmsterdam Pharma Company N.V. stock pay dividends?
No, NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next NewAmsterdam Pharma Company N.V. dividend payment date?
NewAmsterdam Pharma Company N.V. (NAMS) stock does not pay dividends to its shareholders.
What is the beta indicator for NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. (NAMS) has a beta rating of -0.02. This means that it has an inverse relation to market volatility.